New hope for rare immune disorder: long-term drug safety trial now recruiting
NCT ID NCT06990529
First seen Feb 18, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This study looks at the long-term safety of a drug called leniolisib for people with primary immunodeficiency disorders linked to PI3K signaling. It is for patients who were in a previous leniolisib study. The goal is to see if the drug remains safe and helps control immune problems over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PIDS LINKED TO PI3K are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IIS La Fe
RECRUITINGValencia, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lahey Hospital & Medical Center
RECRUITINGBurlington, Massachusetts, 01805, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Institute of Health
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.